Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Oncolytics Biotech in a research report ...
HC Wainwright issued their Q1 2025 EPS estimates for shares of Zevra Therapeutics in a note issued to investors on Thursday, ...
3d
Stocktwits on MSNCore Scientific Stock Gains As HC Wainwright Reiterates Rating On CoreWeave's $12B OpenAI Deal: Retail Stays Extremely BullishShares of Core Scientific Inc. (CORZ) gained almost 8% in Tuesday’s regular session and extended gains during after-hours ...
H.C. Wainwright raised the firm’s price target on ProQR Therapeutics (PRQR) to $12 from $10 and keeps a Buy rating on the shares. The firm says ...
2d
Fintel on MSNHC Wainwright & Co. Initiates Coverage of Perspective Therapeutics (CATX) with Buy RecommendationFintel reports that on March 13, 2025, HC Wainwright & Co. initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with ...
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on IN8bio (INAB) to $6 from $8 and keeps a Buy rating on the ...
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest ...
Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision ...
REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema achieved 15.7% weight loss compared to 3.1% with placebo, ...
Fintel reports that on March 7, 2025, HC Wainwright & Co. initiated coverage of Surf Air Mobility (NYSE:SRFM) with a Buy recommendation. As of March 4, 2025, the average one-year price target for ...
Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation. As of March 4, 2025, the average one-year price target for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results